ArticleCancer medicine2021
Aggressiveness of care at end of life in patients with high-grade glioma.
Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Defining end-of-life in glioblastoma multiforme: a systematic review.Journal of neuro-oncology · 2025Pooled it
- Documented advance care planning elements and end-of-life care patterns in malignant glioma vs. major solid tumors: a single-center retrospective study.Journal of neuro-oncology · 2025Article
- End-of-life care in glioblastoma: A population-based study.Neuro-oncology · 2025Article
- Early integration or last consultation: in-house palliative care involvement for hospitalized patients in tertiary medicine-a retrospective analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Prospective assessment of end-of-life symptoms and quality of life in patients with high-grade glioma.Neuro-oncology practice · 2024Article
- Patterns of care at the end of life: a retrospective study of Italian patients with advanced breast cancer.BMC palliative care · 2024Observational
- Characterization of patients with brain metastases referred to palliative care.BMC palliative care · 2024Article
- Pattern of care of brain tumor patients in the last months of life: analysis of a cohort of 3045 patients in the last 10 years.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- Effect of palliative care decisions making on hospital service use at end-of-life in patients with malignant brain tumors: a retrospective study.BMC palliative care · 2023Article
- Palliative Care and End-of-Life Issues in Patients with Brain Cancer Admitted to ICU.Medicina (Kaunas, Lithuania) · 2023Review
- Neurosurgical Clinical Trials for Glioblastoma: Current and Future Directions.Brain sciences · 2022Review
- Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma.Frontiers in medicine · 2022Article
- Aggressiveness of care at end of life in patients with high-grade glioma.Cancer medicine · 2021Article
- Palliative care in patients with glioblastoma: A systematic review.Medicine internationalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with high-grade glioma (HGG) face unique challenges toward the end of life (EoL), given their aggressive trajectory and neurologic deterioration. Aggressiveness of medical care at EoL has been identified as an important quality metric for oncology patients. At this time, limited data exist around the nature of EoL care of patients with HGG.
methodsPatients with HGG and palliative care (PC) referral seen between 2010 and 2015 were identified (N = 80). Of these, N = 52 met inclusion criteria. Random selections of patients with (1) HGG not referred to PC (n = 80), and (2) non-CNS cancers with PC referral (n = 80) were identified for comparison. A composite score of aggressiveness of medical care at EoL was calculated for each patient from predetermined variables. A time of eligibility for PC was defined for each patient when predetermined criteria based on symptom burden, functional status, and prognosis were met.
resultsAmong the patients analyzed with HGG referred to PC, 59.6% (N = 31) were referred as inpatients, and 53.8% (N = 28) were referred within the last 12 weeks of life. Patients with HGG had similar aggressiveness of care at EoL regardless of PC referral, and HGG patients had less aggressive care at EoL than patients with non-CNS cancers (p = 0.007). Care was more aggressive at EoL in HGG patients who received late versus early PC referrals (p = 0.012). Motor weakness at time of eligibility (OR = 2.55, p = 0.002) and more disease progressions (OR = 1.25, p = 0.043) were associated with less aggressive care at EoL.
conclusionsEarly clinical- and disease-related features predict the aggressiveness of medical care at EoL in patients with HGG. Formal PC consultation is used infrequently and suboptimally in patients with HGG. Our data suggest that the role of PC in improving EoL outcomes in HGG warrants further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.